Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

STUDY OF DOSE DENSE CMF (Cyclophosphamide, Methotrexate, Fluorouracil) as an Alternative to AC (Doxorubicin, Cyclophosphamide) in 2 Regimens in EARLY STAGE BREAST CANCER for Patients Greater or Equal to 70

NCT07768436 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT07768436
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07768436 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
STUDY OF DOSE DENSE CMF (Cyclophosphamide, Methotrexate, Fluorouracil) as an Alternative to AC (Doxorubicin, Cyclophosphamide) in 2 Regimens in EARLY STAGE BREAST CANCER for Patients Greater or Equal to 70
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Recruiting
Start date
August 11, 2026
Completion date
August 11, 2030
Enrollment
76 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma of the breast, breast cancer, triple negative breast cancer